2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

2:30PM-4:00PM: Abstract Number: 1867

Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration

4M089 ACR Abstract: Spondyloarthritis Incl PsA–Clinical III: Treatment of Axial SpA (1864–1869)

2:30PM-4:00PM: Abstract Number: 1868

Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)

4M089 ACR Abstract: Spondyloarthritis Incl PsA–Clinical III: Treatment of Axial SpA (1864–1869)

2:30PM-4:00PM: Abstract Number: 1855

Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus

4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

2:30PM-4:00PM: Abstract Number: 1862

Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Very Low Circulating Low-Density Lipoprotein Concentration Levels Are Associated with Pro-Atherogenic Biomarkers

4M086 ACR Abstract: RA–DX, Manifestations, & Outcomes II: DX & Prognosis I (1858–1863)

2:30PM-4:00PM: Abstract Number: 1836

Fibromyalgia Diagnosis and Biased Assessment: Sex, Prevalence, Biology and Bias

4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

2:30PM-4:00PM: Abstract Number: 1838

Fibromyalgia, Beyond the 2016 Establishment. an Analysis of Novel Symptom Clusters for Differentiating Fibromyalgia from Other Chronic Pain Disorders

4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

2:30PM-4:00PM: Abstract Number: 1826

From Cancer to Autoimmunity : A New Model of Rheumatoid Arthritis Emerging from a Constitutional Genetic Approach Used in Low Penetrance Cancers

4M085 ACR Abstract: RA–Animal Models (1822–1827)

2:30PM-4:00PM: Abstract Number: 1827

Genetic Ablation of Phd Finger Protein 19 Gene Promotes Autoimmune Arthritis in Mice

4M085 ACR Abstract: RA–Animal Models (1822–1827)

2:30PM-4:00PM: Abstract Number: 1828

Gut-Joint T Cell Trafficking in a Model of Bacteria-Driven Murine IBD-Spa

4M088 ACR Abstract: Spondyloarthritis Incl PsA–Basic Science (1828–1833)

2:30PM-4:00PM: Abstract Number: 1878

Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index

4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

2:30PM-4:00PM: Abstract Number: 1842

Implementation of an African American Popular Opinion Leader Model to Address Disparities in Lupus Knowledge and Care

4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

2:30PM-4:00PM: Abstract Number: 1843

Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations

4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

2:30PM-4:00PM: Abstract Number: 1866

Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis

4M089 ACR Abstract: Spondyloarthritis Incl PsA–Clinical III: Treatment of Axial SpA (1864–1869)

2:30PM-4:00PM: Abstract Number: 1883

Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden

4M091 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Population-Based Studies(1881–1886)

2:30PM-4:00PM: Abstract Number: 1875

Influence of Setting an Upper Limit of the Modified Rodnan Skin Score As an Inclusion Criterion in Systemic Sclerosis Clinical Trials on the Ratio of Skin Fibrosis Progression Vs. Improvement – an Analysis of the Genisos Cohort

4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].